Organon & Co. (NYSE:OGN) Trading Up 6.6% – Should You Buy?

Organon & Co. (NYSE:OGN)’s share price rose 6.6% during mid-day trading on Friday . The stock traded as high as $7.97 and last traded at $8.0150. Approximately 2,933,624 shares traded hands during mid-day trading, a decline of 51% from the average daily volume of 5,927,529 shares. The stock had previously closed at $7.52.

Analyst Ratings Changes

Several brokerages recently commented on OGN. Morgan Stanley cut their price target on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 11th. JPMorgan Chase & Co. dropped their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, November 11th. Barclays assumed coverage on Organon & Co. in a report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 target price for the company. Zacks Research downgraded Organon & Co. from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Finally, Piper Sandler lowered Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target on the stock. in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $8.38.

Organon & Co. Price Performance

The company has a 50-day moving average of $7.91 and a 200-day moving average of $8.53. The company has a debt-to-equity ratio of 9.69, a quick ratio of 1.20 and a current ratio of 1.75. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 0.62 and a beta of 0.58.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a return on equity of 123.06% and a net margin of 3.01%.The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.52 billion. During the same quarter last year, the business posted $0.90 EPS. The firm’s revenue was down 5.3% on a year-over-year basis. As a group, equities research analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Investors of record on Monday, February 23rd will be paid a $0.02 dividend. The ex-dividend date is Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.0%. Organon & Co.’s payout ratio is 11.27%.

Institutional Investors Weigh In On Organon & Co.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Hantz Financial Services Inc. grew its position in Organon & Co. by 293.8% during the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock worth $26,000 after buying an additional 1,995 shares during the period. Foster Dykema Cabot & Partners LLC purchased a new stake in shares of Organon & Co. during the 3rd quarter worth approximately $29,000. Farther Finance Advisors LLC grew its holdings in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after acquiring an additional 2,033 shares during the period. SouthState Corp increased its stake in Organon & Co. by 1,857.0% in the 2nd quarter. SouthState Corp now owns 3,914 shares of the company’s stock valued at $38,000 after purchasing an additional 3,714 shares in the last quarter. Finally, Rothschild Investment LLC raised its holdings in Organon & Co. by 73.1% during the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after purchasing an additional 1,646 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.